Firms agree to look at new HIV/Aids actionDecember 2008
Seventeen large pharmaceuticals companies are to invest more in producing treatments for HIV/Aids in poor countries.
Their decision follows a meeting with the United Nations secretary-general Ban Ki-moon, who urged them to do more to combat Aids and HIV in the developing world.
The companies’ plan of action has yet to be finalized but Ban said they have agreed to ‘invest further in research and development of new HIV-related medicines adapted to resource-limited settings to be used safely in children, adolescents, pregnant women and other adults’.
In addition, they will put more resources into Aids prevention, including vaccines and pre-and post-exposure prophylaxis.
The companies at the meeting included Abbott, Boehringer Ingelheim, GlaxoSmithKline and Pfizer.
Ban said after the meeting: ‘Despite gains, the epidemic continues to outstrip our best efforts. Only one-third of those who need anti-retroviral treatment in low- and middle-income countries are getting it. Collectively, we still have more work to do.’
Already a member? click here to login